Shark-cartilage extract AE-941 for stage III lung cancer

MS-N139 · Cancer control · Negative randomized evidence · Human evidence · Appraised 26 October 2026

Does the standardized shark-cartilage extract AE-941 (Neovastat) improve survival when added to chemoradiotherapy for unresectable stage III non-small-cell lung cancer?

Evidence at a glance

Evidence label: Disproven in this setting by a large randomized phase III trial
Benefit: No overall-survival or time-to-progression advantage was demonstrated.
Certainty: Moderate to high for AE-941 added to the studied 2000–2006 chemoradiotherapy regimens; this does not test every cartilage product or every cancer.
Risk: The trial did not justify exposing patients to cost, treatment burden or the risk of delaying effective care for this purpose.

What was studied

Intervention and population: AE-941 was a standardized, water-soluble shark-cartilage extract, not an interchangeable over-the-counter powder. The multicenter phase III trial enrolled 379 eligible patients with previously untreated, unresectable stage III non-small-cell lung cancer at academic and community sites in the United States and Canada.

Design and regimen: Participants were randomly assigned to oral AE-941 120 mL twice daily (n=188) or matching placebo (n=191). Both groups received induction chemotherapy followed by concurrent chemotherapy and chest radiotherapy. Overall survival was the primary endpoint.

What the evidence found

Median overall survival was 14.4 months with AE-941 (95% CI 12.6–17.9) and 15.6 months with placebo (95% CI 13.8–18.1); the difference was not statistically significant (P=.73). Time to progression also did not improve.

Earlier uncontrolled and small studies had suggested antiangiogenic activity. The randomized result matters more: it directly tested whether adding the product helped people live longer and found that it did not.

How to interpret it

This is negative cancer-control evidence, not merely an absence of research. It does not support AE-941 or other shark-cartilage products as lung-cancer therapy.

The finding is specific to unresectable stage III disease and the chemoradiotherapy used at that time. It should not be stretched into claims about symptom support, but neither should laboratory antiangiogenic effects be used to override the human survival result.

Practical safety context

Do not replace or postpone evidence-based lung-cancer treatment with shark cartilage. Products sold as supplements may differ substantially from AE-941 in identity, purity and dose. People with swallowing difficulty, nausea, bleeding risk or complex medication regimens should discuss any supplement with the oncology pharmacist.

Questions for the care team

What outcome am I hoping this product will change, and was that outcome actually improved in a randomized trial?
Could the supplement complicate nutrition, medication adherence or chemoradiotherapy?
Which evidence-based supportive-care options address the symptom or concern that prompted interest in shark cartilage?

Funding and conflicts

The trial was supported partly by an NCI Community Clinical Oncology Program cooperative agreement. Aeterna Zentaris supplied AE-941 and placebo and provided supplemental monitoring and data-collection funding; it did not design or conduct the trial and could review the manuscript before submission. The paper reported no author financial disclosures.

Sources

Last literature search: 26 October 2026. Record appraisal: 26 October 2026. This page is educational and does not replace individualized medical advice. Laboratory effects, biomarkers, symptom changes or an uncontrolled response must not be interpreted as proof of tumor control, delayed recurrence or longer survival.